ECT and Brain Stimulation Therapies

1. Start with the patient, not the machine

A 72-year-old with psychotic depression has stopped drinking, believes she is already dead and cannot weigh treatment information. Your first task is not “book ECT.” Stabilise dehydration and nutrition, assess catatonia and delirium, establish the indication and urgency, test decision-specific capacity, find the lawful pathway, obtain an anaesthetic opinion and document the cognitive baseline—in parallel.[4][5]

2. Which syndromes justify ECT?

Strongest established indication: severe major depression. ECT outperforms simulated ECT and, in the trials synthesised by the UK ECT Review Group, is highly effective for acute depressive illness. Urgency, psychotic features, profound psychomotor change, prior response and failure or unsuitability of other treatments shape when it moves earlier.[1]

Catatonia: treat the syndrome and the cause. Give benzodiazepine treatment first in many non-malignant presentations, but arrange ECT urgently when catatonia is malignant or otherwise life-threatening, or when an adequate benzodiazepine trial is ineffective or cannot be used. Reserve malignant catatonia for catatonia with pronounced autonomic abnormality, typically hyperthermia and autonomic dysfunction; dehydration or hyponatraemia from poor intake may be life-threatening but does not alone establish the malignant subtype. Continue the medical and neurological work-up; lorazepam response does not prove a primary psychiatric cause.[5]

Mania, schizophrenia and other conditions need qualified language. ECT can be used for severe or prolonged mania when rapid control is required or other options have failed. In schizophrenia it is adjunctive in selected catatonic or clozapine-resistant illness; contemporary clozapine augmentation evidence comes from a later meta-analysis, not the old 2005 Cochrane review. Parkinson motor symptoms and neuroleptic malignant syndrome are specialist rescue uses supported mainly by lower-level evidence, not routine first-line indications.[4][8]

3. Classify the modalities correctly

TMS parameters are protocols, not definitions. Conventional high-frequency left-DLPFC rTMS and low-frequency right-DLPFC rTMS are common depression approaches. THREE-D showed 3-minute intermittent theta-burst stimulation was non-inferior to 37.5-minute 10 Hz rTMS in its trial population. SNT delivered ten personalised iTBS sessions daily for five days—50 total, not 50 per day—and requires replication and service-specific governance.[3][9][10][11]

tDCS and related tES

A common research depression montage places anodal stimulation over left DLPFC with a contralateral frontal return, usually 1–2 mA for about 20–30 minutes, often on 5 weekdays per week for several weeks. Current density, electrode area, montage, session count and concurrent treatment matter; these are study-pattern ranges, not a universal prescription. Individual-patient meta-analysis supports an antidepressant signal, but response is variable and cognition data do not justify calling tDCS a cognitive enhancer.[19][20]

The two cited individual-patient meta-analyses support only the qualified efficacy and cognition statements above. They do not establish individual adverse-effect frequencies, a universal contraindication list, home-use equivalence or current device authorisation. For practice, use the named device's instructions and a current local safety/regulatory source; verify skin and implant considerations, comorbidity and supervision requirements there rather than importing an unsourced global checklist. tACS and other tES waveforms have thinner disorder-specific evidence.[19][20]

Magnetic seizure therapy

MST uses a high-output magnetic train to cross seizure threshold and generate a generalised seizure under general anaesthesia, oxygenation, neuromuscular blockade and EEG/motor monitoring. Coil, frequency, train, threshold titration and course are research-protocol variables; do not import outpatient rTMS parameters. Small heterogeneous studies suggest antidepressant activity and possible cognitive advantages relative to ECT, but do not establish routine-care equivalence, long-term safety or a standard prescription. Treat MST as investigational with ECT-like anaesthetic and seizure risks.[18]

Implanted VNS and DBS

VNS uses a cervical vagal lead and implanted pulse generator delivering intermittent stimulation. Output current, frequency, pulse width and on/off cycle are titrated over visits; benefit, when it occurs, is delayed, so VNS is not rescue treatment for physiological compromise or imminent danger. Discuss surgery, infection or hardware failure, hoarseness, cough, throat discomfort, dyspnoea/dysphagia, possible sleep-disordered breathing and MRI/device precautions. The evidence base has limited sham-controlled acute certainty.[21]

The exact US boundary is FDA P970003/S050: adjunctive long-term treatment of chronic or recurrent depression in adults aged at least 18 who are currently in a major depressive episode and have not adequately responded to four or more adequate antidepressant treatments. It is neither a global indication nor an emergency treatment.[21]

DBS places stereotactic intracranial electrodes connected to a pulse generator; target, amplitude, pulse width and frequency are programmed over months. Depression studies use different targets and small samples, with mixed blinded-trial results and uncertain durability. Discuss haemorrhage, infection, seizure, hardware/revision/battery burdens, stimulation-related mood or behavioural effects and continuing suicide-risk monitoring. DBS for depression remains investigational.[22]

In the US, H050003 is a humanitarian device exemption for bilateral anterior-limb-of-internal-capsule stimulation as an adjunct to medication and alternative to anterior capsulotomy in adults with chronic, severe, treatment-resistant OCD who have failed at least three SSRIs. An HDE probable-benefit pathway is not ordinary approval of DBS for depression. Selection requires specialist multidisciplinary care, acceptable neurosurgical risk, lawful consent and ability to attend long-term programming and follow-up.[22]

Esketamine is a drug comparator

The current US Spravato prescribing information, revised March 2026, uses 28-mg devices. Adult TRD induction is 56 or 84 mg twice weekly for 4 weeks, then response-led less-frequent maintenance; TRD may be treated as monotherapy or with an oral antidepressant. For depressive symptoms in MDD with acute suicidal ideation or behaviour, the label is 84 mg twice weekly for 4 weeks, reducible to 56 mg for tolerability, with an oral antidepressant. Effectiveness in preventing suicide or reducing suicidal ideation/behaviour has not been demonstrated, and improvement does not remove a need for hospitalisation.[13]

US treatment requires the Spravato REMS, direct observation in a certified setting and at least 2 hours of monitoring for sedation, dissociation, respiratory depression including pulse oximetry, and blood pressure. Do not drive until the next day after restful sleep. Contraindications are aneurysmal vascular disease or AVM, history of intracerebral haemorrhage and hypersensitivity—not all cardiovascular disease. Assess psychosis, misuse risk, pregnancy, cognition and urinary symptoms. TRANSFORM-1 did not meet its prespecified primary efficacy endpoint and cannot source the later monotherapy label.[13]

Regulatory viva answer. In the US, 21 CFR 882.5940 places an ECT device in Class II only for catatonia or a severe major depressive episode associated with major depressive disorder or bipolar disorder in patients aged 13 years or older who are treatment-resistant or require rapid response; other intended uses remain Class III. That is a device classification boundary, not a universal clinical guideline or legal consent rule.[4]

4. Mechanism: say “multi-level”, not “reset”

The seizure is necessary for conventional ECT, but no single molecular or imaging mechanism explains efficacy. Mechanistic review supports interacting acute neurochemical and network-plasticity hypotheses while emphasising heterogeneity and the absence of a proven unitary causal chain. Avoid claiming that a BDNF “surge,” hippocampal neurogenesis or default-mode “normalisation” is established as the human therapeutic mechanism.[15]

5. Assessment: prove indication, safety and authority

Psychiatric formulation. Confirm the syndrome, severity, urgency, prior treatment at actual dose and duration, adherence, previous ECT response, comorbidity, substance exposure, suicide and violence risk, vulnerability, nutrition and hydration. Use a syndrome-relevant rating scale consistently; the number supports, but never replaces, clinical judgement.[4]

Organic exclusion is targeted. In late first presentation, fluctuating attention, focal signs, fever, new seizure, atypical catatonia or rapid cognitive decline, investigate medication toxicity, electrolyte/endocrine disturbance, infection, epilepsy, structural disease and autoimmune encephalitis as indicated. There is no universal FBC–U&E–LFT–CT battery for everyone; tests follow history, examination and anaesthetic risk.[5]

Cognition needs two lenses. Record subjective memory concerns and objective baseline performance, then repeat during and after the course. Acute disorientation, impaired new learning and retrograde/autobiographical memory loss must be discussed. Group-average objective performance often improves after the acute post-treatment period, but that does not negate an individual's persistent autobiographical loss.[6][4]

Catatonia at the bedside

Use a structured instrument such as the Bush–Francis Catatonia Rating Scale to describe signs and track change, but diagnose clinically and search for the cause. A lorazepam challenge can use 1–2 mg IV or IM, or 2 mg orally; reassess after about 5 minutes IV, 15 minutes IM or 30 minutes orally. About a 50% scale reduction supports a response but is not perfectly specific, and a negative challenge does not exclude catatonia.[5]

6. Capacity, consent and law

Capacity is decision- and time-specific: can the person understand, retain, use or weigh the relevant information, and communicate a choice under the applicable test? Depression, psychosis, catatonia, detention or refusal does not automatically remove capacity. Seek voluntary, pressure-free consent; revisit it before sessions; make clear that consent can be withdrawn.[4]

7. Medical and anaesthetic risk: no invented absolutes

There is no universally accepted list of absolute contraindications. Raised intracranial pressure with mass effect, unstable or recent cardiovascular or cerebrovascular disease, unstable aneurysm, phaeochromocytoma and severe pulmonary or anaesthetic risk are high-risk states requiring senior multidisciplinary assessment, optimisation and a setting able to rescue foreseeable complications. The decision is benefit versus risk, not a rote “three-month” exclusion.[4]

Pre-anaesthesia work-up is individualised. Follow current ANZCA standards or the local equivalent for consultation, preparation, fasting, facilities, skilled assistance, monitoring and recovery. ANZCA does not prescribe an ECT-specific induction drug, neuromuscular blocker or anticholinergic regimen.[4]

Medication review is not a universal hold list. Balance psychiatric destabilisation against seizure and anaesthetic effects. Lithium can increase delirium or prolonged-seizure risk, particularly with renal impairment and older age; benzodiazepines and anticonvulsants can raise threshold, but abrupt withdrawal may be unsafe; theophylline can increase prolonged-seizure or status risk. A 2025 systematic review found few reported major bleeding or thromboembolic events when ECT was delivered during therapeutic warfarin or DOAC use, but evidence is observational and sparse: confirm indication, agent, renal function, adherence, INR when relevant, bleeding/thrombotic risk and interacting procedures. Bridging and a fixed INR ceiling are not universal ECT rules. Adjust diabetes treatment to fasting and glucose risk rather than automatically omitting every agent.[4][16]

8. Conduct one modern ECT treatment

[4]

Succinylcholine safety screen. Avoid it or use an anaesthetist-planned non-depolarising alternative for pseudocholinesterase deficiency/prolonged apnoea risk, malignant-hyperthermia susceptibility, major burns or denervation, severe neuromuscular disease, existing hyperkalaemia or another hyperkalaemia-prone state. Plan reversal where relevant and do not stop assisted ventilation before adequate neuromuscular and respiratory recovery.[4]

The immediate autonomic sequence can include parasympathetic bradycardia followed by sympathetic tachycardia and hypertension. Select haemodynamic treatment for the patient's risk; routine atropine, beta-blockade or arterial cannulation is not universal. For a cardiac implantable electronic device, identify device and pacing dependence, interrogate when indicated and have external pacing/defibrillation rescue. Disable ICD anti-tachycardia detection/therapy before ECT and keep it disabled through the full treatment session, including ictal and postictal sympathetic tachycardia; restore it only after the session under the device plan. Pacemaker asynchronous programming is a separate, dependence- and device-specific decision—not automatic.[17]

9. Stimulus prescription and course

These are attributed teaching ranges from the 2023 practice guideline, not manufacturer-independent prescriptions. Ultrabrief bilateral ECT lacks supporting evidence and is not recommended in that guideline. Re-titrate or adjust for rising threshold, poor seizure quality, nonresponse or cognitive burden rather than chasing a fixed duration.[2][4]

An acute course has no magic count. Many services treat two or three times weekly and many courses fall near 6–12 treatments, but frequency and total number depend on urgency, response, adverse effects, placement and local practice. Review after every treatment; stop when benefit plateaus, harms outweigh further gain, consent is withdrawn or authority ends.[4]

10. Cognitive and medical adverse effects

Electrode placement, pulse width, stimulus dose, treatment frequency, age, baseline cognition and concomitant illness influence cognitive risk. Discuss the tension honestly: objective group means often recover after the acute period, while individual patients may describe persistent, meaningful autobiographical loss. “No cognitive side effects” and “permanent brain damage” are both poor consent language; current evidence does not show convincing structural neuronal injury from modern ECT, but that does not erase lived memory harm.[6][4]

Modern ECT has low medical morbidity in population samples, but risk is concentrated in people with major comorbidity and depends on anaesthetic and service quality. Avoid an unsupported universal mortality slogan such as “1 in 80,000”; explain that serious events are rare, give the service's audited figures if available, and personalise the cardiovascular, respiratory and neurological risk.[7]

Separate efficacy from safety timing. Old 15-second motor or 25-second EEG rules do not define adequacy, but continuing ictal activity beyond 120 seconds should prompt an attempt at termination; more than 180 seconds is prolonged in the cited guideline. Maintain airway, oxygenation and ventilation, confirm EEG activity, call the anaesthetist/ECT lead and follow the rehearsed protocol using a benzodiazepine, the induction anaesthetic or barbiturate, or protocol-selected phenytoin/valproate. Continue EEG to resolution, check glucose/electrolytes and causal medicines, observe for non-convulsive activity and change the next prescription. A tardive seizure after recovery requires emergency assessment.[4]

11. Nonresponse and relapse prevention

Before declaring nonresponse, verify diagnosis, stimulus delivery, placement, dose relative to threshold, treatment number, medications that raise threshold and whether the rating trajectory is genuinely flat. Options include increasing dose, moving from unilateral to bilateral placement, changing pulse width or revisiting the diagnosis; the urgency–cognition trade-off should be re-consented.[2][4]

Relapse risk after a successful acute course is substantial. Agree the post-ECT antidepressant, mood-stabilising or antipsychotic strategy for the underlying illness and consider continuation ECT when prior relapse, medication resistance or preference supports it. “Continuation” commonly refers to roughly the first six months and “maintenance” thereafter, but the interval is adjusted to response and tolerability—not a compulsory weekly–fortnightly–monthly ladder. McCall 2018 supports a quality-of-life outcome in older adults; it should not be misquoted as stand-alone proof that one fixed continuation schedule prevents relapse.[14]

12. Special populations

Pregnancy and postpartum. ECT can be used when expected benefits outweigh risks; evidence is largely observational. Coordinate psychiatry, obstetrics, anaesthesia and neonatology as gestation requires. Consider aspiration and aortocaval risks, position later pregnancy appropriately, and individualise fetal assessment. Discuss transient fetal bradycardia, uterine contractions and preterm labour rather than promising that ECT is universally “safe in all trimesters.”[12][4]

Older adults. Age is not a contraindication and response can be strong, but cardiac disease, frailty, delirium and baseline cognition alter risk. Right-unilateral ultrabrief treatment may reduce cognitive burden but can trade speed or efficacy; severe psychotic depression with dehydration may justify a faster bilateral approach after shared decision-making.[6][7]

Children and adolescents. Use specialist multidisciplinary assessment and the exact local consent or tribunal route. The US Class II ECT-device boundary begins at age 13 only for the specified catatonia or severe-depressive-episode indications; it does not create clinical indication or legal authority elsewhere.[4]

13. Regional and evidence boundaries

14. Exam synthesis

Ward-round test 1 — catatonia with fever and autonomic instability

Treat as malignant catatonia until proved otherwise: intensive medical assessment and supportive care, search for neurological/medical/drug causes, stop unsafe dopamine antagonism, begin syndrome-directed treatment and arrange urgent ECT rather than imposing a routine multi-day benzodiazepine wait.[5]

Ward-round test 2 — a 25-second rule appears on the chart

Remove it. Document EEG morphology, generalisation, post-ictal suppression, motor expression, stimulus dose, medications and clinical trajectory. Duration is one observation, not a binary efficacy threshold.[4]

Ward-round test 3 — a detained patient says no

Detention does not itself authorise ECT. Assess capacity for this decision now, explore reasons and communication needs, check advance preferences, identify the jurisdiction-specific statutory pathway and safeguards, and document urgency. Do not substitute family agreement for lawful authority.[4]

References

1. [1]UK ECT Review Group Efficacy and safety of electroconvulsive therapy in depressive disorders: a systematic review and meta-analysis Lancet, 2003.PMID 12642045
2. [2]Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities Archives of General Psychiatry, 2000.PMID 10807482
3. [3]Mutz J, Vipulananthan V, Carter B, et al. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis BMJ, 2019.PMID 30917990
4. [4]Thirthalli J, Sinha P, Sreeraj VS Clinical Practice Guidelines for the Use of Electroconvulsive Therapy Indian Journal of Psychiatry, 2023.PMID 37063631
5. [5]Rogers JP, Oldham MA, Fricchione G, et al. Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology Journal of Psychopharmacology, 2023.PMID 37039129
6. [6]Semkovska M, McLoughlin DM Objective cognitive performance associated with electroconvulsive therapy for depression: a systematic review and meta-analysis Biological Psychiatry, 2010.PMID 20673880
7. [7]Blumberger DM, Seitz DP, Herrmann N, et al. Low medical morbidity and mortality after acute courses of electroconvulsive therapy in a population-based sample Acta Psychiatrica Scandinavica, 2017.PMID 28922451
8. [8]Wang G, Zheng W, Li XB, et al. ECT augmentation of clozapine for clozapine-resistant schizophrenia: A meta-analysis of randomized controlled trials Journal of Psychiatric Research, 2018.PMID 30144667
9. [9]Blumberger DM, Vila-Rodriguez F, Thorpe KE, et al. Effectiveness of theta burst versus high-frequency repetitive transcranial magnetic stimulation in patients with depression (THREE-D): a randomised non-inferiority trial Lancet, 2018.PMID 29726344
10. [10]Cole EJ, Stimpson KH, Bentzley BS, et al. Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression American Journal of Psychiatry, 2020.PMID 32252538
11. [11]Cole EJ, Phillips AL, Bentzley BS, et al. Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial American Journal of Psychiatry, 2022.PMID 34711062
12. [12]Bobo WV, Moore O, Hurley CB, et al. Modified electroconvulsive therapy for perinatal depression: scoping review Frontiers in Psychiatry, 2025.PMID 40901266
13. [13]Fedgchin M, Trivedi M, Daly EJ, et al. Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1) International Journal of Neuropsychopharmacology, 2019.PMID 31290965
14. [14]McCall WV, Lisanby SH, Rosenquist PB, et al. Effects of continuation electroconvulsive therapy on quality of life in elderly depressed patients: A randomized clinical trial Journal of Psychiatric Research, 2018.PMID 29195125
15. [15]Leaver AM, Espinoza R, Wade B, Narr KL Parsing the Network Mechanisms of Electroconvulsive Therapy Biological Psychiatry, 2022.PMID 35120710
16. [16]Khalid A, Khalid A, Waite S, Plevin D Exploring the use of electroconvulsive therapy in the anticoagulated population: A systematic review Australian and New Zealand Journal of Psychiatry, 2025.PMID 39252452
17. [17]Purohith AN, Vaidyanathan S, Udupa ST, et al. Electroconvulsive Therapy in Patients With Cardiac Implantable Electronic Devices: A Case Report and Systematic Review of Published Cases Journal of ECT, 2023.PMID 35482902
18. [18]Chen M, Yang X, Liu C, et al. Comparative efficacy and cognitive function of magnetic seizure therapy vs. electroconvulsive therapy for major depressive disorder: a systematic review and meta-analysis Translational Psychiatry, 2021.PMID 34420033
19. [19]Brunoni AR, Moffa AH, Fregni F, et al. Transcranial direct current stimulation for acute major depressive episodes: meta-analysis of individual patient data British Journal of Psychiatry, 2016.PMID 27056623
20. [20]Martin DM, Moffa A, Nikolin S, et al. Cognitive effects of transcranial direct current stimulation treatment in patients with major depressive disorder: An individual patient data meta-analysis of randomised, sham-controlled trials Neuroscience and Biobehavioral Reviews, 2018.PMID 29660416
21. [21]Bottomley JM, LeReun C, Diamantopoulos A, et al. Vagus nerve stimulation (VNS) therapy in patients with treatment resistant depression: A systematic review and meta-analysis Comprehensive Psychiatry, 2019.PMID 31978785
22. [22]Wu Y, Mo J, Sui L, et al. Deep Brain Stimulation in Treatment-Resistant Depression: A Systematic Review and Meta-Analysis on Efficacy and Safety Frontiers in Neuroscience, 2021.PMID 33867929